When is it appropriate to stop? Developing an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis

To develop an M&E strategy that enables country programs to effectively implement IDA, and to determine when LF transmission has been sufficiently interrupted such that MDA with IDA can be stopped.